research Pembrolizumab-Induced Autoimmune Hepatitis
Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.
Search
for
Sort by
Research
870-900 / 1000+ resultsresearch Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib
Gefitinib can cause hair loss without scarring.
research Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options
Allergic reactions to blood thinners are rare but can be serious, requiring careful testing and alternative treatments.
research Medikamentöse Therapie der BPH Ist eine Kombinationstherapie mit 5α-Reduktasehemmern und α-Rezeptorenblockern sinnvoll?
Combination therapy is more effective for prostate volumes over 60 ml.
research Real-World Effectiveness of JAK Inhibitors for Alopecia Totalis and Alopecia Universalis: A Single-Center Experience
JAK inhibitors are effective and safe for treating severe alopecia areata.
research Janus kinase inhibitors for alopecia areata
JAK inhibitors offer new hope for treating severe alopecia areata.
research Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.
research Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children
Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
research JAK Inhibitors: A New Weapon in the Skin Care Providers' Arsenal.
JAK inhibitors show promise in treating difficult skin diseases.
research Effectiveness of Abrocitinib in Adolescent Alopecia Areata: A Prospective Observational Pilot Study
Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
research Interaction of antiretroviral medications with finasteride
Antiretrovirals can affect finasteride's effectiveness, so dose adjustments may be needed for men on HIV treatment.
research LB1256 TRIV-509, a dual inhibitor of KLK5 and KLK7, rapidly improves barrier integrity and markers of epidermal differentiation in atopic dermatitis skin explants
TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
research Tofacitinib for the treatment of lichen planopilaris: A case series
Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
research JAK inhibition decreases the autoimmune burden in Down syndrome
JAK inhibition may help manage autoimmune conditions in Down syndrome.
research Blood Donors on Medication – an Approach to Minimize Drug Burden for Recipients of Blood Products and to Limit Deferral of Donors
Donors on most medications can donate certain blood products without waiting, except for specific drugs that need a waiting period.
research 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
research 861 EGFR/MEK inhibitor therapy induces partial hair follicle immune privilege collapse in vivo and ex vivo
research Recovery of resistant alopecia areata treated with tofacitinib: An 8-year-old child's case report
Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.
research Tumor necrosis factor-induced alopecia: alternative pathology and therapy
TNF-inhibitor induced alopecia can be treated effectively with different therapies.
research PC-SPES Studies Promising, But Manufacturer Shuts Down
Promising cancer treatments were found, but the manufacturer closed.
research Effectiveness and safety of baricitinib in severe alopecia areata: 48‐week results
Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
research Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen
Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
research Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib
Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
research 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.
research Tangent screens are still useful in the assessment of vigabatrin induced visual field defects
Tangent screens help detect visual field defects from vigabatrin.
research Alopecia areata
Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
research Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
research DRUG NEWS
The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
research Apremilast and tofacitinib exert differential effects in the humanized mouse model of alopecia areata
Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
research Management of hair loss associated with endocrine therapy in patients with breast cancer: an overview
Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.